Weekly insulin efsitora alfa is non-inferior to daily insulin degludec for reducing HbA1c in type 1 diabetes
1. Once weekly efsitora demonstrated non-inferiority compared with degludec with regards to change in HbA1c. 2. Patients in the efsitora ...
Tag: insulin degludec
Once-weekly insulin icodec non-inferior to daily insulin degludec in patients with type 1 diabetes
1. Mean HbA1c reduction at 26 weeks was comparable in the weekly icodec and daily degludec groups. 2. The risk ...
Once weekly tirzepatide is superior to daily insulin degludec for treatment of uncontrolled type 2 diabetes
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
